Abacavir Use Linked to Increased Incidence of MACE
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 8, 2024 -- For patients with HIV in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, use of abacavir was associated with an increased incidence of major adverse cardiovascular events (MACE), according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich.
Carl J. Fichtenbaum, M.D., from the University of Cincinnati, and colleagues examined the role of prior and current use of antiretroviral agents (ART) on the development of MACE in a trial involving 7,769 participants aged 40 to 75 years on ART for at least 180 days.
The median duration of ART use was 9.5 years, with variation by country. The researchers found that 22, 86, 49, and 47 percent of participants reported prior exposure to abacavir, tenofovir (TDF), thymidine analogs (AZT/d4T), and protease inhibitors (PIs), respectively. At study entry, 13, 61, 10, and 26 percent were using abacavir, TDF, AZT/d4T, and PIs, respectively. Entry regimens included two nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-NRTI, integrase strand transfer inhibitor, or PI (47, 25, and 19 percent, respectively). Both former and current use of abacavir was associated with a higher incidence of MACE in adjusted analyses including the baseline regimen. No association was seen for former or current use of other ART agents with MACE.
"Former and current use of abacavir was associated with a higher incidence of subsequent major adverse cardiovascular events in the REPRIEVE trial," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 -- In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events...
Increased Risk for CVD Seen for Women With Premenstrual Disorders
THURSDAY, July 17, 2025 -- Women with premenstrual disorders (PMDs) have an increased risk for cardiovascular diseases (CVDs), according to a study published online July 11 in...
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.